Kai Kysenius
Overview
Explore the profile of Kai Kysenius including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
344
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Abdeen A, Trist B, Nikseresht S, Harwood R, Roudeau S, Rowlands B, et al.
Acta Neuropathol
. 2025 Mar;
149(1):22.
PMID: 40042537
Atypical wild-type superoxide dismutase 1 (SOD1) protein misfolding and deposition occurs specifically within the degenerating substantia nigra pars compacta (SNc) in Parkinson disease. Mechanisms driving the formation of this pathology...
2.
Anttalainen A, Havula E, Kysenius K, Toppila I, Miettinen T, Lassenius M, et al.
Ann Hematol
. 2024 Dec;
PMID: 39676133
Infections are a clinically significant cause of mortality in multiple myeloma (MM) patients. The high number of infections in MM patients is due to the immunosuppressive effects of the disease...
3.
Mattila K, Tiainen L, Vikkula J, Kreutzman A, Engstrom-Risku M, Kysenius K, et al.
Future Oncol
. 2024 Sep;
20(40):3491-3505.
PMID: 39345100
First-line (1L) immunotherapy has yielded superior overall survival (OS) in metastatic melanoma (MM) but some patients are ineligible for immunotherapy or need rapid response with 1L targeted therapy (TT). Retrospective...
4.
Kysenius K, Anttalainen A, Toppila I, Miettinen T, Lassenius M, Lievonen J, et al.
Ann Hematol
. 2024 Sep;
103(11):4837.
PMID: 39271524
No abstract available.
5.
Hilton J, Kysenius K, Liddell J, Mercer S, Rautengarten C, Hare D, et al.
Neurotherapeutics
. 2024 Aug;
21(5):e00432.
PMID: 39164165
Multiple sclerosis (MS) is a debilitating affliction of the central nervous system (CNS) that involves demyelination of neuronal axons and neurodegeneration resulting in disability that becomes more pronounced in progressive...
6.
Kysenius K, Anttalainen A, Toppila I, Miettinen T, Lassenius M, Lievonen J, et al.
Ann Hematol
. 2024 Jul;
103(8):2931-2943.
PMID: 38963447
Advances in treatment have improved the survival of multiple myeloma (MM) patients, but the disease remains incurable. Here, in this nationwide retrospective real-world evidence (RWE) study, we report the patient...
7.
Hilton J, Kysenius K, Liddell J, Mercer S, Paul B, Beckman J, et al.
Sci Rep
. 2024 Mar;
14(1):5929.
PMID: 38467696
The copper compound Cu(atsm) has progressed to phase 2/3 testing for treatment of the neurodegenerative disease amyotrophic lateral sclerosis (ALS). Cu(atsm) is neuroprotective in mutant SOD1 mouse models of ALS...
8.
Liddell J, Hilton J, Kysenius K, Billings J, Nikseresht S, McInnes L, et al.
Mol Neurodegener
. 2024 Feb;
19(1):14.
PMID: 38317225
Background: Ferroptosis is a form of regulated cell death characterised by lipid peroxidation as the terminal endpoint and a requirement for iron. Although it protects against cancer and infection, ferroptosis...
9.
Niskanen L, Hannula M, Kysenius K, Kaijala S, Lassenius M, Valle T
J Diabetes
. 2024 Jan;
16(5):e13491.
PMID: 38273701
Aims: To describe the clinical characteristics and medication purchases of insulin-treated adults in Finland at index (January 1, 2012 or first insulin purchase) and December 31, 2019. Additionally, to describe...
10.
Hilton J, Kysenius K, Liddell J, Mercer S, Hare D, Buncic G, et al.
Metallomics
. 2024 Jan;
16(1).
PMID: 38178638
Demyelination within the central nervous system (CNS) is a significant feature of debilitating neurological diseases such as multiple sclerosis and administering the copper-selective chelatorcuprizone to mice is widely used to...